CClinicalTrials.gg
RecruitingNCT03404336Updated May 5, 2026

Study on 30 Outpatients With Chronic Migraine Treated With Well-Being Therapy or With a Control Therapy

An interventional study of Well-Being Therapy and Control condition in Chronic Migraine, sponsored by University of Florence. Recruiting at 2 sites in Italy. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-05.

Sponsored by University of Florence · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Chronic migraine is a disabling type of migraine and is often resistant to treatment. Non-pharmacological interventions have been investigated as potential treatment although, unfortunately, the literature on their efficacy is poor and showed mixed results. Well-Being Therapy (WBT) is a brief psychotherapy which has shown efficacy in decreasing the relapse rates of depression in adults, in generalized anxiety disorder and in cyclothymia. It can be implemented to empower psychological well-being. The aim of the present study is to test the efficacy of WBT in a sample of patients with chronic migraine to verify if it reduces the disability due to migraine and distress, it increases the psychological well-being as well as the level of euthymia.

Read the detailed description

Chronic migraine is a disabling type of migraine and is often resistant to treatment. Non-pharmacological interventions have been investigated as potential treatment although, unfortunately, the literature on their efficacy is poor and showed mixed results. The psychological interventions tested up to now are the Acceptance and Commitment Therapy and the Mindfulness. Well-Being Therapy (WBT) is a brief psychotherapy which has been manualized in 2016 and has shown efficacy in randomized clinical trials. It showed to be effective in decreasing the relapse rates of depression in adults, it showed to be effective in generalized anxiety disorder and in cyclothymia. Thus, psychological well-being can be implemented and empowered via a specific psychotherapy and this implementation might produce a protecting effect, thus favoring prevention. The aim of the present study is to test the efficacy of WBT in a sample of patients with chronic migraine. First the efficacy of WBT will be verified in terms of disability due to migraine. Then, the efficacy of WBT will be measured in terms of psychological well-being, euthymia, and distress. For this purpose, 30 chromic migraine outpatients will be enrolled in a randomized, controlled, open clinical study.

02

Conditions studied

  • Chronic Migraine

Keywords

  • migraine
  • chronic
  • well-being therapy
  • psychotherapy
  • therapy
03

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. able and interested in participating to the present research project, as proved by signed Informed consent;
  2. 18-65 years of age;
  3. Italian mother tongue;
  4. diagnosis of chronic migraine according to the International Classification of Headache Disorders. Thus, presenting specific features (i.e., unilateral and pulsating pain of moderate or severe intensity, which is aggravated or precipitated by routine physical activities and is combined with nausea and/or vomiting, photophobia, and phonophobia) and migraine headache on ≥ 15 days per month;
  5. headache chronicity for a minimum of 1 year and pattern of headache symptoms stable for a period of at least 6 months;
  6. no pharmacological therapy or dietary supplements use for chronic migraine OR pharmacological therapy/dietary supplement use for chronic migraine stable since at least 3 months;
  7. psychotropic medication allowed only if stable since at least three months.

Exclusion criteria

Exclusion criteria:

  1. diagnosis of medication overuse headache;
  2. co-occurrence of psychiatric disorder(s) according to the Diagnostic and Statistical Manual of mental disorders (DSM) 5th edition as diagnosed via the MINI International Neuropsychiatric Interview;
  3. co-occurrence of chronic unstable medical conditions;
  4. being pregnant or lactating;
  5. under exogeneous hormones treatment (i.e., hormonal contraceptives, postmenopausal hormone therapy);
  6. any other condition that, according to the Investigators' opinion, may alter the ability of the patient to follow study procedures.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Well-being therapy

    WBT will be used as the only non-pharmacological therapeutic strategy and 8 sessions will be delivered every other week with a duration of 60 minutes each. The manualized WBT will be used (Fava, 2016). Thus, the initial phase will be concerned with self-observation of psychological well-being. Once the instances of well-being will be properly recognized, the patient will be encouraged to identify thoughts, beliefs, and behaviors leading to premature interruption of well-being (intermediate phase). The final part will involve cognitive restructuring of dysfunctional dimensions of psychological well-being and meeting the challenge that optimal experiences may entail.

    Behavioral: Well-Being Therapy

  • Placebo comparator
    Control condition

    The control condition will include 8 be-weekly sessions based on Lifestyle and well-being National Institute for health and Care Excellence (NICE) guidelines (https://www.nice.org.uk/guidance/lifestyle-and-wellbeing) and on World Health Organization 12 steps to healthy eating (http://www.euro.who.int/en/health-topics/disease-prevention/nutrition/a-healthy-lifestyle). These sessions will inform participants about well-being and which lifestyles can influence it.

    Other: Control condition

Interventions

  • BehavioralWell-Being Therapy

    Session 1: identifying and setting episodes of wellbeing into situational context. Session 2: identifying interfering thoughts and behaviors. Session 3: illustrating autonomy, reflecting and practicing it. Session 4: illustrating environmental mastery, reflecting and practicing it. Session 5: illustrating positive relations with others, reflecting and practicing it. Session 6: illustrating personal growth, reflecting and practicing it. Session 7: illustrating self-acceptance, reflecting and practicing it. Session 8: illustrating purpose in life, reflecting and practicing it.

  • OtherControl condition

    Session 1: illustrating the concept of lifestyle and well-being. Session 2 and session 3: illustrating healthy eating and steps to healthy eating. Session 4: illustrating physical exercise and how it promotes health. Session 5: illustrating smoking and tobacco and how they can damage health. Session 6: illustrating alcohol and how it can damage health. Session 7: illustrating drugs misuse and how it can damage health. Session 8: illustrating sexual health. No access to specific WBT ingredients will be allowed.

05

What researchers measure

Primary outcomes

  1. disability due to migraine

    level of disability due to migraine assessed via the Migraine Disability Assessment Score (score from 0 to \>21, for total score \> 6 disability is clinically relevant)

    Time frame: from baseline to 3-month follow up

  2. frequency of migraine attacks

    frequency of migraine attacks assessed via a daily self-report headache diary (higher the frequency, higher the severity of migraine)

    Time frame: from baseline to 3-month follow up

  3. duration of migraine attacks

    duration of migraine attacks assessed via a daily self-report headache diary (higher the duration, higher the severity of migraine)

    Time frame: from baseline to 3-month follow up

  4. intensity of migraine attacks

    intensity of migraine attacks assessed via a daily self-report headache diary (higher the intensity, higher the severity of migraine)

    Time frame: from baseline to 3-month follow up

Secondary outcomes

  1. level of anxiety and depression

    the level of anxiety and depression will be assessed via the Symptom Questionnaire (total score from 0 to 92, higher is the total score and worse is the symptomatology)

    Time frame: from baseline to 3-month follow up

  2. level of psychological well-being

    assessed via the World Health Organization-Five Well-Being Index (WHO 5) (total score from 0 to 25, higher total score means higher quality of life)

    Time frame: from baseline to 3-month follow up

  3. level of psychological well-being

    assessed via Psychological Well-Being Questionnaire (PWB) (total score from 84 to 504, higher score corresponds to higher psychological well-being)

    Time frame: from baseline to 3-month follow up

  4. the level of euthymia

    the level of euthymia will be assessed via the euthymia scale (total score from 0 to 10, higher score corresponds to higher level of euthymia)

    Time frame: from baseline to 3-month follow up

06

Study locations

1 of 2 sites recruiting
  • Fiammetta COSCI
    Florence, Florence 50135, Italy
    Not yet recruiting
  • Centro Cefalee e Farmacologia Clinica
    Florence, Italy, Italy
    • Francesco De Cesaris, MD · Contact
    Recruiting
07

References and documents

Publications

  • Mansueto G, De Cesaris F, Geppetti P, Cosci F. Protocol and methods for testing the efficacy of well-being therapy in chronic migraine patients: a randomized controlled trial. Trials. 2018 Oct 16;19(1):561. doi: 10.1186/s13063-018-2944-5. PubMed 30326932 ↗

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT03404336
Lead sponsor
University of Florence
Responsible party
Fiammetta Cosci (Associate Professor in Clinical Psychology, University of Florence) — Principal investigator
First posted
Jan 19, 2018
Start date
Oct 1, 2018
Primary completion
Dec 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
May 5, 2026

Study contacts

Fiammetta COSCI, Prof.
Contact
fiammetta.cosci@unifi.it
0552755066 ext. 0039

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion